The Molecular Oncology of Drug Resistance: Targets, Drugs and Chemical Biology

Author(s): Giovanni Luca Beretta*.

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 33 , 2019

[1]
El Hassouni, B.; Sarkisjan, D.; Vos, J.C.; Giovannetti, E.; Peters, G.J. Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance. Curr. Med. Chem., 2019, 26(33), 6020-6032.
[2]
Zanforlin, E.; Zagotto, G.; Ribaudo, G.A. Chemical approach to overcome tyrosine kinase inhibitors resistance : learning from chronic myeloid leukemia. Curr. Med. Chem., 2019, 26(33), 6033-6052.
[3]
Ferroni, C.; Varchi, G. Non-steroidal androgen receptor antagonists and prostate cancer: a survey on chemical structures binding this fast-mutating target. Curr. Med. Chem., 2019, 26(33), 6053-6073.
[4]
Stankovic, T.; Dinic, J.; Podolski-Renic, A.; Musso, L.; Buric, S.S.; Dallavalle, S.; Pesic, M. Dual inhibitors as a new challenge for cancer multidrug resistance treatment. Curr. Med. Chem., 2019, 26(33), 6074-6106.
[5]
Guo, J.; Mattos, B.D.; Tardy, B.L.; Moody, V.M.; Xiao, G.; Ejima, H.; Cui, J.; Liang, K.; Richardson, J.J. Porous inorganic and hybrid systems for drug delivery: future promise in combatting drug resistance and translation to botanical applications. Curr. Med. Chem., 2019, 26(33), 6107-6131.
[6]
Arrighetti, N.; Corbo, C.; Evangelopoulos, M.; Pasto, A.; Zuco, V.; Tasciotti, E. Exosome-like nanovectors for drug delivery in cancer. Curr. Med. Chem., 2019, 26(33), 6132-6148.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 26
ISSUE: 33
Year: 2019
Page: [6018 - 6019]
Pages: 2
DOI: 10.2174/0929867326666190913194602

Article Metrics

PDF: 26
HTML: 3